Advertisement
UK markets open in 1 hour 30 minutes

  • NIKKEI 225

    38,055.53
    +427.05 (+1.13%)
     

  • HANG SENG

    17,655.71
    +371.17 (+2.15%)
     

  • CRUDE OIL

    83.92
    +0.35 (+0.42%)
     

  • GOLD FUTURES

    2,349.50
    +7.00 (+0.30%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,346.44
    +94.86 (+0.19%)
     

  • CMC Crypto 200

    1,385.37
    +2.79 (+0.20%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Novartis blocked from selling Neupogen copycat until September

Reuters - UK Focus

By Andrew Chung

NEW YORK, July 21 (Reuters) - Novartis AG (Xetra: 904278 - news) unit Sandoz must wait until September to sell Zarxio, the first biosimiar drug approved in the United States and a copycat version of Amgen (Hanover: AMG.HA - news) Inc's Neupogen, a U.S. appeals court said on Tuesday.

Ruling in a patent infringement lawsuit filed by Amgen (Xetra: 867900 - news) , the U.S. Court of Appeals for the Federal Circuit, the country's top patent court, said that it would maintain an injunction on the Sandoz drug until Sept. 2. (Reporting by Andrew Chung; Editing by Chizu Nomiyama)